Director, Biostatistics Laboratory
Eric Polley, PhD is an Associate Professor in the Department of Public Health Sciences at The University of Chicago where he is the faculty director for the Data Science concentration in the Master of Public Health program. Dr. Polley was previously an Assistant Professor of Biostatistics in the Department of Quantitative Health Sciences at Mayo Clinic (2015-2021) and a mathematical statistician in the Biometric Research Branch at the U.S. National Cancer Institute (2012-2015). Dr. Polley received his PhD in biostatistics from the University of California, Berkeley in 2010. With Mark van der Laan, they developed the Super Learner ensemble prediction methodology. His research area involves the development and evaluation of prediction methods, innovative methods for diagnostic and prognostic prediction, and precision medicine clinical trial design.
National Cancer Institute
MD
Fellow - Computational Biology
2012
University of California, Berkeley
CA
PhD - Biostatistics
2010
Columbia University
NY
MS - Biostatistics
2005
Saint John's University
MN
BA - Mathematics
2003
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer.
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer. NPJ Breast Cancer. 2024 Jul 13; 10(1):57.
PMID: 39003306
Intermuscular coherence as an early biomarker for amyotrophic lateral sclerosis: The protocol for a prospective, multicenter study.
Intermuscular coherence as an early biomarker for amyotrophic lateral sclerosis: The protocol for a prospective, multicenter study. PLoS One. 2024; 19(5):e0303053.
PMID: 38776297
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy.
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy. Ophthalmol Retina. 2024 May 11.
PMID: 38735641
Clot composition and recanalization outcomes in mechanical thrombectomy.
Clot composition and recanalization outcomes in mechanical thrombectomy. J Neurointerv Surg. 2024 Apr 23; 16(5):466-470.
PMID: 37419694
Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk.
Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk. Nat Cardiovasc Res. 2024 Apr; 3(4):431-440.
PMID: 38846711
Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain.
Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain. Am J Hum Genet. 2024 Mar 07; 111(3):584-593.
PMID: 38417439
Derivation of an Annualized Claims-Based Major Adverse Cardiovascular Event Estimator in Type 2 Diabetes.
Derivation of an Annualized Claims-Based Major Adverse Cardiovascular Event Estimator in Type 2 Diabetes. JACC Adv. 2024 Apr; 3(4):100852.
PMID: 38939660
Outcomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods Study.
Outcomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods Study. Clin Diabetes. 2024; 42(3):371-387.
PMID: 39015157
Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems-based Resource.
Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems-based Resource. Mol Cancer Ther. 2023 Nov 01; 22(11):1270-1279.
PMID: 37550087
Signal processing and machine learning with transdermal alcohol concentration to predict natural environment alcohol consumption.
Signal processing and machine learning with transdermal alcohol concentration to predict natural environment alcohol consumption. Exp Clin Psychopharmacol. 2024 Apr; 32(2):245-254.
PMID: 37824232
NCI Director's award for the development of the NCI-MATCH clinical trial
National Cancer Institute
2015